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Abstract
Impaired endogenous fibrinolysis is an adverse prognostic biomarker in acute coronary syndrome (ACS). Abnormally 
dense in vitro fibrin thrombi have been demonstrated in ACS patients and related to hypofibrinolysis using cumbersome, 
laboratory-based methods. We aimed to assess endogenous fibrinolysis using a point-of-care technique and relate this to 
clot architecture. From patients with ST-segment elevation myocardial infarction (STEMI), venous blood was drawn imme-
diately on arrival to assess thrombotic status. Blood was assessed using the point-of-care Global Thrombosis Test which 
measures occlusive thrombus formation under high shear and subsequently endogenous fibrinolysis (lysis time, LT). Two 
samples per patient were run in parallel. In one channel, the measurement was allowed to proceed as normal. In the other, 
after occlusion, thrombus was extracted, washed, fixed in glutaraldehyde, dried, sputter-coated, and assessed using scanning 
electron microscope. Endogenous fibrinolysis was strongly associated fibrin fibre thickness (p = 0.0001). As LT increased 
(less efficient fibrinolysis), the fibrin network of the thrombus was significantly more compact and dense, with thinner fibrin 
fibres and smaller gaps. Fibrin fibre thickness correlated inversely with LT (r = − 0.89, p = 0.001). Adverse clot architecture 
in vitro is directly related to impaired endogenous fibrinolysis using a relatively new point-of-care technique in patients with 
STEMI. This may transform the relevance of fibrin clot architecture from an off-line laboratory association to being directly 
relevant to endogenous fibrinolysis at the patient bedside, which could be used as a near-patient test to guide prognosis and 
assess the effect of treatment.
Highlights
• Abnormally dense in vitro fibrin thrombi have been asso-
ciated with hypofibrinolysis using cumbersome labora-
tory-based methods.
• We show for the first time that, in STEMI patients, 
impaired endogenous fibrinolysis measured using a rela-
tively new point-of-care technique is strongly related to 
adverse fibrin clot characteristics in vitro.
• This may transform the relevance of fibrin clot archi-
tecture from an off-line laboratory association to being 
directly relevant to endogenous fibrinolysis at the patient 
bedside.
• This could be used as a near-patient test to guide prog-
nosis and assess the effect of treatment.
Introduction
The likelihood of coronary thrombosis causing arterial 
occlusion in ST-elevation myocardial infarction (STEMI) 
depends on the effectiveness of endogenous fibrinolysis 
[1]. Impaired fibrinolysis is a recently-described adverse 
prognostic biomarker in acute coronary syndrome [2–4]. 
Abnormally dense fibrin thrombi have been demonstrated 
in populations at risk of coronary thrombosis [5] and related 
to hypofibrinolysis using cumbersome, laboratory-based, 
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low-shear turbidimetric methods. We aimed to assess endog-
enous fibrinolysis under high shear using a near-patient tech-
nique and relate this to clot architecture.
Methods
This prospective observational study was approved by 
National Research Ethics Service and the UK Health 
Research Authority (ClinicalTrials.gov identifier: 
NCT02562690). Following consent, 50 patients presenting 
with STEMI with a view to primary percutaneous coronary 
intervention (PPCI) were screened to assess thrombotic 
status, to identify 15 patients who were included. Dual 
antiplatelet therapy was administered in the ambulance 
pre-arrival. Patients with coagulopathy, malignancy, sep-
sis, blood dyscrasias (platelets < 100 × 109/L, haemoglobin 
< 80 g/L) or taking anticoagulants were excluded.
Assessment of endogenous fibrinolysis
Venous blood drawn upon arrival, before heparin or PPCI, 
was immediately assessed using the point-of-care Global 
Thrombosis Test (GTT, Thromboquest Ltd., UK) situated in 
the catheterization laboratory. This measures the time taken 
for occlusive thrombus formation under high shear (occlu-
sion time, OT) and subsequently the time until restart of 
flow due to endogenous fibrinolysis (lysis time, LT) [3, 4]. 
Two samples per patient were run in parallel. In one chan-
nel, the measurement was allowed to proceed as normal. In 
the other, immediately after occlusion, the thrombus was 
extracted and fixed.
Scanning electron microscopy
The thrombus was washed in Na-cacodylate buffer, fixed in 
2.5% glutaraldehyde, critically dried with alcohol (5–100%) 
followed by hexamethyldisilazane, sputter-coated with gold 
with Quorum 150 [6], and imaged using scanning electron 
microscope (SEM) (Lambda Photometrics Ltd., UK). Thick-
ness of fibrin fibres (n = 100) from nine areas per thrombus 
were measured. Fibrin density was calculated using a Scentis 
Database Image software with a Multiple Phase Percentage 
Processing package, based on differential light intensities, 
to derive total fibrin fibre area (% per visual field [p.v.f.]) 
indicating fibrin density and void space-gap (% p.v.f.), 
an indirect measure of clot density. SEM was performed 
blinded to thrombotic status results.
Statistical analysis
Patients were divided into quartiles based on LT. 
Kruskal–Wallis test was used to assess differences between 
groups, Wilcoxon signed-rank test to investigate differences 
in different areas within clots and correlation assessed with 
Spearman’s method. Analyses were performed with Stata 
V15.1 (StataCorp, USA).
Results
Endogenous fibrinolysis was strongly associated fibrin 
fibre thickness (p = 0.0001). As LT increased (less efficient 
fibrinolysis), the fibrin network of the thrombus was signifi-
cantly more compact and dense, with thinner fibrin fibres 
and smaller gaps (Fig. 1). Fibrin fibre thickness correlated 
inversely with LT (r = − 0.89, p = 0.001) but not with OT 
(p = 0.688).
Clinical characteristics, hemoglobin, hematocrit, platelet 
count, fibrinogen, troponin and pain-to-door time were not 
related to LT or fibrin thickness. After accounting for clini-
cal parameters known to impact fibrinolysis (age, hyperten-
sion, diabetes, haematological and biochemical characteris-
tics), the relationship between LT and fibrin fibre thickness 
remained significant (p = 0.005) on multivariable regression.
Conclusion
Patients with STEMI who exhibit impaired endogenous 
fibrinolysis under high shear using a point-of-care technique, 
create in vitro thrombi with much denser fibrin meshwork 
composed of thinner fibrin fibres and smaller gaps, than 
patients with effective fibrinolysis. This is the first study 
correlating a point-of-care measure of endogenous fibrinoly-
sis with in vitro fibrin clot characteristics. Previous studies 
have shown unfavourable clot characteristics in high-risk 
groups, using cumbersome, off-line, turbidimetric labora-
tory methods employing low shear. This new evidence base 
linking thrombus architecture to cardiovascular risk could 
now be translated from an off-line laboratory association to 
a clinically meaningful, near-patient assessment of endog-
enous fibrinolysis, with the potential to modify risk.
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Fig. 1  Representative SEM images of in vitro thrombus from patients 
with increasing fibrinolysis time (panels a → d), at increasing mag-
nification (1 → 3), and differential light intensities (a4 → d4). Images 
relate directly to LT quartiles in table of clot characteristics (median 
[interquartile range]) below
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